Spots Global Cancer Trial Database for bevacizumab (avastin)
Every month we try and update this database with for bevacizumab (avastin) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Bevacizumab in Treating Patients With Advanced Solid Tumors | NCT00416637 | Unspecified Adu... | Bevacizumab (Av... | 18 Years - | Duke University | |
| Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy With/Without Bevacizumab for Hepatic Metastases From Colorectal Cancer | NCT00200200 | Hepatic Metasta... Colon Cancer Rectal Cancer | Bevacizumab HAI... HAI plus system... | 19 Years - | Memorial Sloan Kettering Cancer Center | |
| Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer | NCT00675597 | Lung Cancer | Bevacizumab (Av... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment | NCT00807573 | Lung Cancer | Paclitaxel Pemetrexed Bevacizumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab | NCT01223235 | Fallopian Tubes... Ovarian Cancer Peritoneal Canc... | bevacizumab and... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery | NCT00242502 | Hepatocellular ... Liver Cancer | Bevacizumab (Av... Erlotinib | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer. | NCT00605722 | Liver Cancer | bevacizumab (Av... erlotinib (Tarc... | 18 Years - | Hoffmann-La Roche | |
| Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer | NCT00846612 | Ovarian Cancer | Doxil Bevacizumab (Av... | 18 Years - | NYU Langone Health | |
| Neoadjuvant FOLFOX Plus Bevacizumab Chemotherapy in Patients With Locally Advanced Colon Cancer | NCT00826800 | Colon Cancer | FOLFOX and beva... | 18 Years - 90 Years | Memorial Sloan Kettering Cancer Center | |
| Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma | NCT01083966 | Vestibular Schw... | Bevacizumab (Av... | 18 Years - | Northwell Health | |
| Escalated Dose of Irinotecan in mCRC | NCT02256800 | Metastatic Colo... | UGT1A1 genotypi... UGTIA1 genotypi... UGTIA1 genotypi... UGT1A1 non-geno... bevacizumab (Av... irinotecan Leucovorin 5-FU | 20 Years - 80 Years | Kaohsiung Medical University Chung-Ho Memorial Hospital | |
| Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer | NCT00658697 | Prostate Cancer | Docetaxel Bevacizumab ADT Bicalutamide | 18 Years - | Dana-Farber Cancer Institute | |
| Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor | NCT01189643 | Sarcoma Desmoplastic Sm... | irinotecan, tem... | 1 Year - 29 Years | Memorial Sloan Kettering Cancer Center | |
| Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab | NCT01223235 | Fallopian Tubes... Ovarian Cancer Peritoneal Canc... | bevacizumab and... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Post-First Progression Use of Bevacizumab in Metastatic Colorectal Cancer (mCRC) | NCT00862342 | Metastatic Colo... | Bevacizumab (Av... | 18 Years - | Asan Medical Center | |
| Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma | NCT00308607 | Metastatic Mela... | Bevacizumab (Av... dacarbazine interferon-alfa... | 18 Years - | University of Turku | |
| Chemotherapy and Avastin Followed by Maintenance Treatment With Avastin +/- Tarceva | NCT00598156 | Metastatic Colo... | erlotinib (Tarc... bevacizumab (Av... | 18 Years - | Lund University Hospital | |
| Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer | NCT01248962 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | carboplatin carboplatin | 21 Years - | Memorial Sloan Kettering Cancer Center | |
| Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer | NCT00271505 | Non-Small Cell ... | Bevacizumab (Av... Carboplatin Docetaxel | 18 Years - | M.D. Anderson Cancer Center | |
| Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer | NCT00271505 | Non-Small Cell ... | Bevacizumab (Av... Carboplatin Docetaxel | 18 Years - | M.D. Anderson Cancer Center | |
| A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen | NCT00615056 | Colorectal Neop... | Bevacizumab (av... FOLFIRI (Irinot... AG-013736 (axit... FOLFOX (oxalipl... AG-013736 (axit... FOLFIRI (irinot... Bevacizumab (av... FOLFOX (oxalipl... | 18 Years - | Pfizer | |
| Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma | NCT00737438 | Esophageal Canc... Gastric Cancer | epirubicin, cis... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer. | NCT00605722 | Liver Cancer | bevacizumab (Av... erlotinib (Tarc... | 18 Years - | Hoffmann-La Roche | |
| Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes | NCT00887809 | Sarcoma Leiomyosarcoma Malignant Fibro... Histiocytoma Angiosarcoma | gemcitabine docetaxel bevacizumab | 18 Years - 75 Years | Memorial Sloan Kettering Cancer Center | |
| Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer. | NCT00337389 | Metastatic Colo... Colon Cancer Rectal Cancer | 5- Fluorouracil... bevacizumab (Av... Leucovorin CoFactor (ANX-5... | 18 Years - | Mast Therapeutics, Inc. | |
| Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors | NCT00395434 | Tumors | Combretastatin ... Bevacizumab (Av... | 18 Years - | Mateon Therapeutics | |
| Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer. | NCT00337389 | Metastatic Colo... Colon Cancer Rectal Cancer | 5- Fluorouracil... bevacizumab (Av... Leucovorin CoFactor (ANX-5... | 18 Years - | Mast Therapeutics, Inc. | |
| Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor | NCT01189643 | Sarcoma Desmoplastic Sm... | irinotecan, tem... | 1 Year - 29 Years | Memorial Sloan Kettering Cancer Center | |
| Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma | NCT00737438 | Esophageal Canc... Gastric Cancer | epirubicin, cis... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma | NCT01492673 | Neuroblastoma Sarcoma | Cyclophosphamid... | - 21 Years | Memorial Sloan Kettering Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
